Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2021, Douglas Lind, M.D. was appointed to the Board of Directors (the "Board") Enveric Biosciences, Inc. (the "Company"), to fill one of the vacancies on the Board and to serve for a term expiring at the next annual meeting of stockholders or until his successor is duly elected and qualified. The Board appointed Dr. Lind to serve on the Audit Committee of the Board.

For his service on the Board, Dr. Lind will be paid an annual compensation of $25,000 and, for his service on the Audit Committee of the Board, Dr. Lind will be paid an annual compensation of $5,000. In addition, the Board approved an equity award to Dr. Lind of 6,794 shares of restricted stock, one-third of which are subject to time-based vesting conditions and two-thirds of which are subject to performance-based vesting conditions.

The Company issued a press release announcing Dr. Lind's appointment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
  No.     Description

99.1        Press Release, dated March 18, 2021

© Edgar Online, source Glimpses